NEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 2021 Wells Fargo Virtual Healthcare Conference. Renalytix’s management is scheduled to participate

Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic NEW YORK and SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Daniel J.

Peer reviewed publication in Journal of Medical Economics supports payer coverage for early-stage risk assessment and care management in the primary care office NEW YORK and SALT LAKE CITY, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the publication of

Berman serves on the board of Loews Corporation, is a member of the board of trustees of Beth Israel Deaconess, and is a former chief financial officer of Harvard University NEW YORK and SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the

NEW YORK, July 26, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 41 st Annual Canaccord Genuity Virtual Global Growth Conference. Renalytix’s management is scheduled to present at the

Hutson to Build on Renalytix Quality and Regulatory Strategy for KidneyIntelX Global Commercialization NEW YORK and SALT LAKE CITY, July 22, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Joseph Hutson as its Vice President of Quality and

Study Results lay foundation for KidneyIntelX repeat testing, reimbursement, and pharma collaborations NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) announces new data demonstrating KidneyIntelX™ can be effective at monitoring therapeutic response and

NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021. Recent Highlights Partnership announced with University of Utah health system to improve

Announces Change of Auditor to Ernst & Young LLP NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced the Company will release fiscal third quarter 2021 financial results on Tuesday, June 15, 2021, before market open.

Enabling expertise in sales, population health and value-driven care models NEW YORK and SALT LAKE CITY, June 07, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced a series of key hires to drive its commercialization strategy in the United States market in light